FIELD: medicine.
SUBSTANCE: invention concerns normalisation of a hypersensibility of thrombocytes to aggregation inductors at a metabolic syndrome (MS). For this purpose within 3 months carry out the therapy including individually picked up hypohigh-calorie diet, the dosed out physical trainings, administration of lovastatin 20 mg in the evening during meal and fozinopril 10 mg of 1 times in the morning.
EFFECT: normalisation of sensitivity of thrombocytes to inductors of aggregation and risk depression thrombotic complications at the expense of depression of the increased level of glycoproteids of thrombocytes at patients with metabolic syndrome.
1 ex, 2 tbl
